Peptide · developed by Capstone Therapeutics
AZX100 is an agent administered by intradermal injection at surgical or keloid scar sites. It has been studied for scar prevention and scar reduction, including keloid scars.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT00825916 | Phase 2 | Scar Prevention | Completed | CAPS |
| NCT00811577 | Phase 2 | Scar Prevention | Completed | CAPS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Scar PreventionScar Reduction
Updated Nov 15, 2026. Something wrong or missing? Report it on the CAPS page.
See CAPS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CAPS catalysts and pipeline →